CULLINAN THERAPEUTICS, INC. Diluted Shares Outstanding (Weighted Average)
CULLINAN THERAPEUTICS, INC. (CGEM) reported Diluted Shares Outstanding (Weighted Average) of 58.34 million shares for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2024-11-07
- CULLINAN THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2024-09-30 was 58.34M shares, a 36.51% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2024-06-30 was 55.05M shares, a 37.80% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2024-03-31 was 43.01M shares, a 5.72% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for the quarter ending 2023-12-31 was 42.81M shares, a 8.56% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 41.55M shares, a 10.91% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 46.64M shares, a 8.27% increase from fiscal 2021.
- CULLINAN THERAPEUTICS, INC. weighted average number of shares outstanding, diluted for fiscal 2021 was 43.08M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2024-09-30 | 58.34M shares 10-Q · filed 2024-11-07 | 56.69M shares derived: average of 2 quarters · filed 2024-11-07 | 52.16M shares 10-Q · filed 2024-11-07 | 49.80M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 55.05M shares 10-Q · filed 2024-08-08 | 49.03M shares 10-Q · filed 2024-08-08 | 46.96M shares derived: average of 3 quarters · filed 2024-08-08 | 45.90M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | 43.01M shares 10-Q · filed 2024-05-15 | 42.91M shares derived: average of 2 quarters · filed 2024-05-15 | 42.85M shares derived: average of 3 quarters · filed 2024-11-07 | 42.13M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | 42.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 42.77M shares derived: average of 2 quarters · filed 2024-11-07 | 41.83M shares derived: average of 3 quarters · filed 2024-11-07 | 41.55M shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 42.73M shares 10-Q · filed 2024-11-07 | 41.34M shares derived: average of 2 quarters · filed 2024-11-07 | 41.13M shares 10-Q · filed 2024-11-07 | 42.55M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 39.95M shares 10-Q · filed 2024-08-08 | 40.31M shares 10-Q · filed 2024-08-08 | 42.48M shares derived: average of 3 quarters · filed 2024-08-08 | 43.27M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 40.68M shares 10-Q · filed 2024-05-15 | 43.75M shares derived: average of 2 quarters · filed 2024-05-15 | 44.37M shares derived: average of 3 quarters · filed 2024-05-15 | 44.87M shares derived: average of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | 46.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 46.22M shares derived: average of 2 quarters · filed 2024-03-14 | 46.27M shares derived: average of 3 quarters · filed 2024-03-14 | 46.64M shares 10-K · filed 2024-03-14 |
| 2022-09-30 | 45.61M shares 10-Q · filed 2023-11-08 | 46.00M shares derived: average of 2 quarters · filed 2023-11-08 | 46.58M shares 10-Q · filed 2023-11-08 | 44.74M shares derived: average of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | 46.38M shares 10-Q · filed 2023-08-10 | 46.39M shares 10-Q · filed 2023-08-10 | 44.45M shares derived: average of 3 quarters · filed 2023-08-10 | 44.20M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 44.43M shares 10-Q · filed 2023-05-11 | 43.49M shares derived: average of 2 quarters · filed 2023-05-11 | 43.47M shares derived: average of 3 quarters · filed 2023-05-11 | 43.43M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 42.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 42.99M shares derived: average of 2 quarters · filed 2023-03-09 | 43.09M shares derived: average of 3 quarters · filed 2023-03-09 | 43.08M shares 10-K · filed 2023-03-09 |
| 2021-09-30 | 43.44M shares 10-Q · filed 2022-11-14 | 43.37M shares derived: average of 2 quarters · filed 2022-11-14 | 43.25M shares 10-Q · filed 2022-11-14 | |
| 2021-06-30 | 43.30M shares 10-Q · filed 2022-08-10 | 42.71M shares 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |